LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

Inicio・Lista de Acciones・Incyte Corp

Incyte Corp

Cerrado

SectorSanidad

97.14 1.71

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

92.12

Máximo

97.89

Métricas clave
By Trading Economics
Ingresos	4.1M 303M
Ventas	-234M 1.3B
P/B Media del Sector	13.445 49.701
BPA	1.81
Margen de beneficios	23.834
Empleados	2,844
EBITDA	-47M 367M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+13.89% upside

Dividendos
By Dow Jones
Próximas Ganancias	28 jul 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-31M 19B
Apertura anterior	95.43
Cierre anterior	97.14

Noticias sobre sentimiento de mercado

By Acuity

14%

86%

22 / 345 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

59.52 / 62.66 Soporte y Resistencia

Incyte Corp Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

20 may 2026, 23:31 UTC

Acciones populares

Stocks to Watch: Intuit, Applied Digital, Osisko, Banzai

20 may 2026, 22:52 UTC

Principales Movimientos del Mercado

Osisko Shares Fall on Planned Convertible Notes Offering

20 may 2026, 23:47 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

20 may 2026, 23:47 UTC

Charlas de Mercado

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

20 may 2026, 23:44 UTC

Ganancias

Musk Is In Total Control of SpaceX. The IPO Filing Has Finally Come. -- Barrons.com

20 may 2026, 23:35 UTC

Charlas de Mercado

Gold Edges Lower Amid Slightly Higher U.S. Treasury Yields -- Market Talk

20 may 2026, 23:30 UTC

Charlas de Mercado

Goodman Well-Placed for Earnings Guidance Upgrade -- Market Talk

20 may 2026, 23:17 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

20 may 2026, 23:17 UTC

Charlas de Mercado

Ryman Healthcare Bull Focusing on Three Areas in FY26 Result -- Market Talk

20 may 2026, 23:15 UTC

Charlas de Mercado

Mainfreight's FY26 Profit Fall May Mask Improving Performance -- Market Talk

20 may 2026, 23:14 UTC

Ganancias

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 4th Update

20 may 2026, 23:02 UTC

Charlas de Mercado

KMD Brands Faces Two Testing Hurdles -- Market Talk

20 may 2026, 22:57 UTC

Charlas de Mercado

Infratil's Other Assets Deserve Attention, Too -- Market Talk

20 may 2026, 22:57 UTC

Charlas de Mercado

Global Energy Roundup: Market Talk

20 may 2026, 22:57 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

20 may 2026, 22:51 UTC

Charlas de Mercado

Australia Shares Set to Rise, Continue Whipsaw Week -- Market Talk

20 may 2026, 22:51 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

20 may 2026, 22:27 UTC

Charlas de Mercado

SpaceX Says It Has Largest Addressable Market in 'Human History' -- Market Talk

20 may 2026, 22:14 UTC

Charlas de Mercado

Moody's Downgrades Mexico's Sovereign Rating -- Market Talk

20 may 2026, 22:10 UTC

Ganancias

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 3rd Update

20 may 2026, 22:00 UTC

Ganancias

Intuit Stock Falls on Earnings -- and the Company Plans to Cut 17% of Its Workforce -- Barrons.com

20 may 2026, 21:38 UTC

Ganancias

Adquisiciones, fusiones, absorciones

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 2nd Update

20 may 2026, 21:27 UTC

Ganancias

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- Update

20 may 2026, 21:20 UTC

Ganancias

Nvidia CFO: Edge Computing Demand Fell Modestly Due to Higher Memory Prices

20 may 2026, 21:19 UTC

Ganancias

Nvidia Still Uncertain Whether Shipping to China Will Be Allowed, CFO Says

20 may 2026, 21:18 UTC

Ganancias

Nvidia on Track to Start Production Shipments of Vera Rubin in Second Half of This Year, CFO Says

20 may 2026, 21:17 UTC

Ganancias

Nvidia Projects $20B in CPU Revenue This Year, CFO Says

20 may 2026, 21:17 UTC

Ganancias

Nvidia CFO: Every Major Hyperscaler Engaged in Deploying Vera CPU

20 may 2026, 21:17 UTC

Ganancias

Nvidia's Vera CPU Opens New $200B Market, CFO Says

20 may 2026, 21:16 UTC

Ganancias

SpaceX IPO Filing Finally Comes. Mars, Musk, and More Big Things to Watch. -- Barrons.com

Comparación entre iguales

Cambio de precio

Incyte Corp previsión

Precio Objetivo

By TipRanks

13.89% repunte

Estimación a 12 Meses

Media 108.88 USD 13.89%

Máximo 135 USD

Mínimo 75 USD

De acuerdo con 18 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Incyte Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

18 ratings

Comprar

Mantener

Vender

De acuerdo con 18 analistas que ofrecen calificaciones bursátiles a para Incyte Corp Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

59.52 / 62.66Soporte y Resistencia

Bullish events outweigh bearish events.

All events are bearish.

Sentimiento

By Acuity

22 / 345 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation